Division of Molecular Pathology, Institute of Cancer Research, London, UK.
Department of Medicine, Royal Marsden Hospital, London and Surrey, UK.
Gut. 2021 Oct;70(10):1904-1913. doi: 10.1136/gutjnl-2020-321016. Epub 2020 Sep 3.
A comprehensive analysis of the immune landscape of pancreatic neuroendocrine tumours (PanNETs) was performed according to clinicopathological parameters and previously defined molecular subtypes to identify potential therapeutic vulnerabilities in this disease.
Differential expression analysis of 600 immune-related genes was performed on 207 PanNET samples, comprising a training cohort (n=72) and two validation cohorts (n=135) from multiple transcriptome profiling platforms. Different immune-related and subtype-related phenotypes, cell types and pathways were investigated using different in silico methods and were further validated using spatial multiplex immunofluorescence.
The study identified an immune signature of 132 genes segregating PanNETs (n=207) according to four previously defined molecular subtypes: metastasis-like primary (MLP)-1 and MLP-2, insulinoma-like and intermediate. The MLP-1 subtype (26%-31% samples across three cohorts) was strongly associated with elevated levels of immune-related genes, poor prognosis and a cascade of tumour evolutionary events: larger hypoxic and necroptotic tumours leading to increased damage-associated molecular patterns (viral mimicry), stimulator of interferon gene pathway, T cell-inflamed genes, immune checkpoint targets, and T cell-mediated and M1 macrophage-mediated immune escape mechanisms. Multiplex spatial profiling validated significantly increased macrophages in the MLP-1 subtype.
This study provides novel data on the immune microenvironment of PanNETs and identifies MLP-1 subtype as an immune-high phenotype featuring a broad and robust activation of immune-related genes. This study, with further refinement, paves the way for future precision immunotherapy studies in PanNETs to potentially select a subset of MLP-1 patients who may be more likely to respond.
根据临床病理参数和先前定义的分子亚型对胰腺神经内分泌肿瘤(PanNETs)的免疫景观进行全面分析,以确定该疾病的潜在治疗弱点。
对 207 个 PanNET 样本进行了 600 个免疫相关基因的差异表达分析,这些样本来自多个转录组分析平台的训练队列(n=72)和两个验证队列(n=135)。使用不同的计算方法研究了不同的免疫相关和亚型相关表型、细胞类型和途径,并使用空间多重免疫荧光进一步验证。
该研究根据先前定义的四个分子亚型(转移样原发性(MLP)-1 和 MLP-2、胰岛素瘤样和中间型)鉴定了一个由 132 个基因组成的免疫特征,该特征可将 PanNETs(n=207)分开。MLP-1 亚型(三个队列中 26%-31%的样本)与免疫相关基因水平升高、预后不良和一系列肿瘤进化事件强烈相关:更大的缺氧和坏死性肿瘤导致损伤相关分子模式(病毒模拟)、干扰素基因途径刺激物、T 细胞炎症基因、免疫检查点靶标以及 T 细胞介导和 M1 巨噬细胞介导的免疫逃逸机制增加。多重空间分析验证了 MLP-1 亚型中巨噬细胞显著增加。
本研究提供了 PanNETs 免疫微环境的新数据,并确定 MLP-1 亚型为具有广泛而强大的免疫相关基因激活的免疫高表型。这项研究为未来 PanNETs 的精准免疫治疗研究铺平了道路,可能选择更有可能响应的 MLP-1 患者子集。